澳優(1717.HK)復牌高開7.57% 獲伊利戰略入股
格隆匯10月28日丨羊奶粉巨頭澳優(1717.HK)今早復牌跳空高開7.57%報9.52港元,市值164億港元。伊利股份昨晚公吿,通過全資子公司金港控股以協議轉讓、認購新股並觸發全面要約義務的方式收購澳優乳業股權,交易價格為10.06港元/股,較停牌前價格8.85港元溢價13.7%。金港將以10.06港元/股的價格購買原股東持有的5.31億股澳優股份,佔澳優已發行股本的30.89%。此外,澳優還將以10.06港元/股的價格向金港定向發行0.9億股新股。交易完成後,金港將持有6.21億股澳優股份,佔澳優已發行股本的34.33%,成為其單一最大股東。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.